The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease: Results from a 1-Year Randomized Controlled Clinical Trial
Open accessAbstract
Background: Combination therapy with a long-acting bronchodilator and an inhaled corticosteroid (ICS) is recommended in patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. The efficacy and tolerability of the combination of budesonide/formoterol have been demonstrated in patients with COPD when administered via the dry powder inhaler (DPI) in a 1-year study and when administered via the hydrofluoroalkane (HFA) pressurized metered-dose inhaler (pMDI) in a 6-month study.Objective: This study assessed the long-term efficacy and tolerability of budesonide/formoterol HFA pMDI in patients with moderate to very severe COPD.Methods: This was a 12-month, randomized, double-blind, double-dummy, parallel-group, active- and placebo-controlled, multicentre study (NCT00206167) of 1964 patients aged ≥40 years with moderate to very severe COPD conducted from 2005 to 2007 at 237 sites in the US, Europe and Mexico. After 2 weeks of treatment based on previous therapy (ICSs, short-acting bronchodilators allowed), patients received one of the following treatments twice daily: budesonide/formoterol pMDI 160/4.5 μg × two inhalations (320/9 μg); budesonide/formoterol pMDI 80/4.5 μg × two inhalations (160/9 μg); formoterol DPI 4.5 μg × two inhalations (9 μg); or placebo.Main outcome measures: The co-primary efficacy variables were pre-dose forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1.Results: Budesonide/formoterol 320/9 μg demonstrated greater improvements in pre-dose FEV1 versus formoterol (p = 0.008), and both budesonide/formoterol doses demonstrated greater improvements in 1-hour post-dose FEV1 versus placebo (p < 0.001). The rate of COPD exacerbations was lower in both budesonide/formoterol groups compared with formoterol and placebo (p ≤ 0.004). Both budesonide/formoterol doses were more effective than placebo (p ≤ 0.006) for controlling dyspnoea and improving health status (St George’s Respiratory Questionnaire). All treatments were generally well tolerated. The incidence of pneumonia was not different for active (3.4–4.0%) and placebo (5.0%) groups.Conclusions: Budesonide/formoterol pMDI (320/9 μg and 160/9 μg) improved pulmonary function and reduced symptoms and exacerbations over 1 year in patients with moderate to very severe COPD. Only budesonide/formoterol pMDI 320/9 μg demonstrated greater efficacy for both co-primary variables compared with formoterol DPI 9 μg. Both budesonide/formoterol pMDI dosages were well tolerated relative to formoterol and placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035 · cited 1×
“Health status was assessed at months 1, 2, 6 and 12 using the StGeorge’s Respiratory Questionnaire (SGRQ).([9,10]) Sleep score, percentage of awakening-free nights (sleep score of 0) and study rescue medication use were assessed as previously described by Tashkin et al.”
Method
Cited by
Bafadhel, M., Peterson, S., De Blas, M. A., Calverley, P. M., Rennard, S. I., Richter, K., & Fagerås, M. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30006-7 · Cited by 442
Self-citationWelte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., & Kessler, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0492oc · Cited by 408
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Kew, K. M., & Seniukovich, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010115.pub2 · Cited by 398
Ferguson, G. T., Rabe, K. F., Martinez, F. J., Fabbri, L. M., Wang, C., Ichinose, M., Bourne, E., Ballal, S., Darken, P., DeAngelis, K., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30327-8 · Cited by 379
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease
Lipson, D. A., Barnacle, H., Birk, R., Brealey, N., Locantore, N., Lomas, D. A., Ludwig-Sengpiel, A., Mohindra, R., Tabberer, M., Zhu, C.-Q., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201703-0449oc · Cited by 327
Metadata
- Authors
- Rennard, S. I., Tashkin, D. P., McElhattan, J., Goldman, M., Ramachandran, S., Martin, U. J., & Silkoff, P. E.
- Venue
- Drugs
- Published
- 2009
- Volume
- 69
- Issue
- 5
- Pages
- 549-565
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2057984874
- Cited by
- 185
- References
- 2
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease: Results from a 1-Year Randomized Controlled Clinical Trial. https://app.cochat.ai/papers/10.2165/00003495-200969050-00004
- The paper
- Rennard, S. I., Tashkin, D. P., McElhattan, J., Goldman, M., Ramachandran, S., Martin, U. J., & Silkoff, P. E. (2009). Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease: Results from a 1-Year Randomized Controlled Clinical Trial. Drugs. https://doi.org/10.2165/00003495-200969050-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.